Krantz S B
Department of Medicine (Hematology), Vanderbilt University School of Medicine, Nashville, Tennessee.
Pharmacotherapy. 1990 Mar-Apr;10(2 ( Pt 2)):15S-21S.
The efficacy of epoetin alfa (recombinant human erythropoietin) has been tested for treating the anemia associated with end-stage renal disease. This anemia is caused by severely decreased levels of erythropoietin, 90% of which is ordinarily produced by healthy kidneys. Treatment with epoetin alfa successfully corrected the anemia of 97% of 333 patients, as evidenced by hematocrit levels that increased by at least 6 percentage points or reached a study target level of 35%, 2 points above current guidelines. The 127 patients who previously required red cell transfusions to maintain an adequate hematocrit became completely transfusion independent after receiving epoetin alfa. Furthermore, treatment with this growth factor alleviated many of the symptoms of uremia, such as loss of energy and appetite. The major side effect observed with epoetin alfa treatment was increased diastolic blood pressure; however, this was well controlled by additional antihypertension medication. There have been no reports of antibody formation in response to this drug. Thus, epoetin alfa is a safe and effective means of treating the anemia caused by chronic renal insufficiency.
已对促红细胞生成素α（重组人促红细胞生成素）治疗终末期肾病相关贫血的疗效进行了测试。这种贫血是由促红细胞生成素水平严重降低所致，其中90%通常由健康的肾脏产生。促红细胞生成素α治疗成功纠正了333例患者中97%的贫血，这由血细胞比容水平至少提高6个百分点或达到35%的研究目标水平所证明，该目标比当前指南高出2个百分点。之前需要输注红细胞以维持足够血细胞比容的127例患者在接受促红细胞生成素α治疗后完全不再需要输血。此外，用这种生长因子进行治疗缓解了许多尿毒症症状，如精力和食欲丧失。促红细胞生成素α治疗观察到的主要副作用是舒张压升高；然而，通过额外的抗高血压药物可很好地控制这一情况。尚无关于对该药物产生抗体形成的报道。因此，促红细胞生成素α是治疗慢性肾功能不全所致贫血的一种安全有效的方法。
